Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and
| Current Price | ₹1,274.55 |
|---|---|
| Market Cap | ₹1,06,131 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 24.8 |
| Return on Equity | 11.84% |
| 52-Week Range | ₹1,148.40 – ₹1,379.70 |
| Beta (1Y) | 0.06 |
| Dividend Yield | 0.63% |
1. Global Generics-89% 2. Pharmaceutical Services and Active Ingredients (PSAI)-12.5% 3. Others-0.6%
Dr.Reddys Lab is trading at ₹1,274.55, with a market capitalisation of ₹1,06,131 Cr.
Dr.Reddys Lab operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Dr.Reddys Lab has a P/E of 24.8 and a return on equity of 11.84%.